Peptide Stack

Tesamorelin + Ipamorelin

Tesa/IPA · tesamorelin ipamorelin blend

Clinic-style blend pairing FDA-approved tesamorelin (Egrifta, GHRH analog for HIV-associated lipodystrophy) with ipamorelin. Sold as one reconstituted vial on some research/clinic menus. Tesamorelin remains a prescription drug; stacking it with a research GHRP is off-label and not a labeled indication.

Not FDA-approved — research chemicalWADA (S2) — prohibited in sport at all times
Reviewed by CalcMyPeptide Editorial Team
Last updated: April 2026Evidence: Low1 peer-reviewed citation
Typical research dose
Tesamorelin 1 mg + ipamorelin 200-300 mcg (clinic blend SKUs vary)
Frequency
1× daily (typically evening, empty stomach)
Half-life
~26–38 min + ~2 h
Common vials
5 mg / 10 mg
CAS
N/A (blend)
Molecular weight
Blend
Dose it
11 mg + 2 mL BAC water → 5.5 mg/mL · 1200 mcg ≈ 22 units (U-100)
Open in calculator

Mechanism of Action

Tesamorelin is FDA-approved GHRH analog (Egrifta) for HIV-associated lipodystrophy, with visceral-fat data on label. Ipamorelin is a research GHRP. Clinic menus sell a single reconstituted vial. That is off-label for tesamorelin’s indication and unapproved as a combination product.

Source: Tesamorelin: FDA Egrifta label, PMID: 20947872. Ipamorelin: see ipamorelin entry.

Dosing Protocol

Typical DoseTesamorelin 1 mg + ipamorelin 200-300 mcg (clinic blend SKUs vary)
Frequency1× daily (typically evening, empty stomach)
Half-Life~26–38 min (tesamorelin) / ~2 hours (ipamorelin)
Common Vial Sizes5 mg, 10 mg

Dosing Protocols

Clinic blend (example)

Dose
Tesamorelin 1 mg + ipamorelin 200–300 mcg
Frequency
Daily SC
Note: Labeled tesamorelin monotherapy for lipodystrophy is 2 mg daily reconstituted with the kit diluent — do not assume the blend matches the PI.

Administration

Route
Subcutaneous
Timing
Often evening, empty stomach in clinic protocols.
Fasting Required?
Yes — inject on an empty stomach

Expected Timeline

Labeled tesamorelin (not the blend)
VAT reduction in HIV lipodystrophy trials over months.

Who Is It For?

Visceral fat / GHRH

Moderate

Tesamorelin has a label. The ipamorelin add-on does not.

Reconstitution Example

Vial
11 mg
Diluent
2 mL
Concentration
5.5 mg/mL
Per Unit (100u syringe)
55 mcg
Dose of 1200 mcg = 21.8 units on a 100-unit insulin syringe
🧮 Calculate Your Exact Tesamorelin + Ipamorelin Dose →

Safety & Considerations

Tesamorelin is prescription. Glucose, IGF-1, injection-site reactions, and hypersensitivity are PI issues. Adding ipamorelin is off-label. WADA S2.

Regulatory & Legal Status

FDA Status (US)
Research Only

Tesamorelin (Egrifta®) is FDA-approved alone. The blend with ipamorelin is off-label / compounded

WADA Status (2026)
Prohibited (S2)

Competitive athletes subject to anti-doping controls should not use Tesamorelin + Ipamorelin.

Classification

Compounded Drug (Rx)

US Compounding: Available via licensed pharmacy Rx

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Dosing Quick Reference

Tesamorelin + Ipamorelin— Dosing Guide
Dose Range
Tesamorelin 1 mg + ipamorelin 200-300 mcg (clinic blend SKUs vary)
Half-Life
~26–38 min (tesamorelin) / ~2 hours (ipamorelin)
Frequency
1× daily (typically evening, empty stomach)
Route
Subcutaneous
5 mg vial10 mg vial
💧 2 mL BAC water📐 5.5 mg/mL💉 55 mcg/unit (100u syringe)
Peptide Stackcalcmypeptide.com

Frequently Asked Questions

Is this FDA-approved as a stack?▼
No. Tesamorelin is approved alone. Ipamorelin is not approved. The vial combo is compounding/clinic practice.

References

  1. Falutz et al. “Tesamorelin for HIV-associated lipodystrophy.” NEJM / related (2010). PMID: 20947872

Looking for a trusted source? See our recommended suppliers →

Independently tested · COA-verified · Save 10% with our exclusive code

← Back to Peptide Library